Colleen Rivard1, Rachel Isaksson Vogel2, Deanna Teoh3. 1. Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Minnesota. 2. Biostatistics and Bioinformatics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. 3. Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Minnesota. Electronic address: dkteoh@umn.edu.
Abstract
STUDY OBJECTIVE: To evaluate if the administration of intraperitoneal bupivacaine decreased postoperative pain in patients undergoing minimally invasive gynecologic and gynecologic cancer surgery. DESIGN: Retrospective cohort study (Canadian Task Force classification II-3). SETTING: University-based gynecologic oncology practice operating at a tertiary medical center. PATIENTS: All patients on the gynecologic oncology service undergoing minimally invasive surgery between September 2011 and June 2013. INTERVENTIONS: Starting August 2012, intraperitoneal administration of .25% bupivacaine was added to all minimally invasive surgeries. These patients were compared with historical control subjects who had surgery between September 2011 and July 2012 but did not receive intraperitoneal bupivacaine. MEASUREMENTS AND MAIN RESULTS: One-hundred thirty patients were included in the study. The patients who received intraperitoneal bupivacaine had lower median narcotic use on the day of surgery and the first postoperative day compared with those who did not receive intraperitoneal bupivacaine (day 0: 7.0 mg morphine equivalents vs 11.0 mg, p = .007; day 1: .3 mg vs 1.7 mg, p = .0002). The median patient-reported pain scores were lower on the day of surgery in the intraperitoneal bupivacaine group (2.7 vs 3.2, p = .05) CONCLUSIONS: The administration of intraperitoneal bupivacaine was associated with improved postoperative pain control in patients undergoing minimally invasive gynecologic and gynecologic cancer surgery and should be further evaluated in a prospective study.
STUDY OBJECTIVE: To evaluate if the administration of intraperitoneal bupivacaine decreased postoperative pain in patients undergoing minimally invasive gynecologic and gynecologic cancer surgery. DESIGN: Retrospective cohort study (Canadian Task Force classification II-3). SETTING: University-based gynecologic oncology practice operating at a tertiary medical center. PATIENTS: All patients on the gynecologic oncology service undergoing minimally invasive surgery between September 2011 and June 2013. INTERVENTIONS: Starting August 2012, intraperitoneal administration of .25% bupivacaine was added to all minimally invasive surgeries. These patients were compared with historical control subjects who had surgery between September 2011 and July 2012 but did not receive intraperitoneal bupivacaine. MEASUREMENTS AND MAIN RESULTS: One-hundred thirty patients were included in the study. The patients who received intraperitoneal bupivacaine had lower median narcotic use on the day of surgery and the first postoperative day compared with those who did not receive intraperitoneal bupivacaine (day 0: 7.0 mg morphine equivalents vs 11.0 mg, p = .007; day 1: .3 mg vs 1.7 mg, p = .0002). The median patient-reported pain scores were lower on the day of surgery in the intraperitoneal bupivacaine group (2.7 vs 3.2, p = .05) CONCLUSIONS: The administration of intraperitoneal bupivacaine was associated with improved postoperative pain control in patients undergoing minimally invasive gynecologic and gynecologic cancer surgery and should be further evaluated in a prospective study.
Authors: Theodoor E Nieboer; Jan C M Hendriks; Marlies Y Bongers; Mark E Vierhout; Kirsten B Kluivers Journal: Obstet Gynecol Date: 2012-01 Impact factor: 7.661